The United Laboratories was founded in 1990 and listed in Hong Kong in 2007 under the stock code 3933.HK. It is engaged in the R&D, manufacturing and sales of pharmaceuticals. Over 30 years of development, TUL has formed a comprehensive pharmaceutical group with four major business segments: finished products, APIs, biopharmaceuticals, and animal healthcare, along with nine production and R&D entities. Our sales network covers over 70 countries and regions, and there are more than 16,000 employees. In 2023, the company achieved revenues exceeding 13.7 billion yuan.

TUL’s finished products consist of 12 major series with over 60 varieties, including both chemical drugs and biological products, spanning fields such as hypoglycemics, anti-infection, analgesics, cough suppressants, antiviral medications, dermatological drugs, anti-hepatitis drugs, ophthalmic products、Health care products and neurological medications. Our APIs and intermediates include nearly 50 varieties across 5 major series, such as 6-APA, penicillin G potassium first crystal, semi-synthetic penicillin, cephalosporins, β-lactamase inhibitors, and carbapenems. The animal healthcare products include nearly 100 varieties across categories for livestock, poultry, ruminants, aquatics, and pets.

TUL is committed to high-quality development driven by technological innovation. We have established multiple R&D institutions covering chemical and biological drug development. Currently, there are over 100 products under research, and more than 100 patents have been granted. These products target diabetes, weight management, NASH, osteoporosis, dry eye syndrome, and skin diseases, laying a solid foundation for cultivating core technology products with market competitiveness.

Since its establishment, TUL has been committed to providing society with high-quality products and services and promoting the high-quality development of the pharmaceutical industry. As one of the leading comprehensive pharmaceutical enterprises in China, the company was ranked 16th in China Top 100 Chemical Pharmaceutical Enterprises 2023, and 23rd in China Top 100 Pharmaceutical Enterprises 2023, and was granted many other awards, including Excellent Enterprise Brand for Pharmaceutical Preparation Export and Excellent Enterprise Brand for APIs Export of China Chemical Pharmaceutical Industry 2021.